Literature DB >> 21868748

Glans-preserving surgery for superficial penile cancer.

Pengchao Li1, Ninghong Song, Changjun Yin, Wei Zhang, Jie Li, Lixin Hua, Zengjun Wang, Gong Cheng.   

Abstract

In this study, we investigated the safety and feasibility of glans-preserving surgery for superficial penile squamous cell carcinoma. Young patients with penile primary tumors exhibiting favorable histologic features were best suited for organ-sparing procedures, enabling them to avoid sexual disturbances. The study included 12 patients, 38-53 years of age (median age 46 years), with superficial lesions involving the glans penis, coronary sulcus, or shaft skin. After clinical staging and grading, those patients were offered a glans-preserving procedure to preserve the normal appearance and functional integrity of the glans penis. Of the 12 patients referred, the tumors were TaG1 in 4 patients, TaG2 in 3, TisG1 in 1, TisG2 in 1, T1G1 in 2, and T1G2 in 1. All patients returned to normal sexual activity 1 month postoperatively. Sexual function and sexual satisfaction were well maintained after surgery. The cosmetic results were considered satisfying/very satisfying by 83% (10 of 12 patients). Follow-up data were available on 12 patients at a mean follow-up of 62.5 months. Only 1 patient had recurrence 6 months after surgery, which was managed by a second glans-preserving surgery without recurrence. With careful patient selection and vigilant follow-up, anatomically suitable superficial penile cancer can be offered this glans-preserving surgery, while preserving function of the penis wherever possible.

Entities:  

Mesh:

Year:  2011        PMID: 21868748     DOI: 10.2164/jandrol.111.013896

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  1 in total

1.  Surgical treatment of primary disease for penile squamous cell carcinoma: A Surveillance, Epidemiology, and End Results database analysis.

Authors:  Yao Zhu; Wei-Jie Gu; Hong-Kai Wang; Cheng-Yuan Gu; Ding-Wei Ye
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.